AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32605697
Drug: Injected allergen-specific
RxNorm normalized name: silk allergenic extract Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected allergen-specific immunotherapy (AIT) for grass pollen allergy
Trial: 32700389
Drug: Physician incentives
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician incentives of $50 per patient per drug class
Trial: 37173792
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Trial: 34008397
Drug: Bedtime levothyroxine
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime levothyroxine administration (group A)
Trial: 34008397
Drug: Early morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early morning levothyroxine administration (group B)
Trial: 32790913
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + Clavulanic acid
Trial: 32790913
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + Clavulanic acid + Probiotics
Trial: 32790913
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics or probiotics (Control)
Trial: 36243020
Drug: Chronic convection-enhanced
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic convection-enhanced delivery of topotecan (146 μM, 200 μL/h for 48 h, followed by a 5-7 day washout period, with four total infusions)
Trial: 35466448
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg sc monthly
Trial: 35466448
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg po weekly
Trial: 34431612
Drug: Scalp acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp acupuncture (ISSA) at parietal midline [MS5], left anterior parietotemporal oblique line [MS6], left posterior parietotemporal oblique line [MS7] for one course of treatment.
Trial: 34431612
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine (control group).
Trial: 35184471
Drug: Nomogram for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram for predicting poor ovarian response (POR) based on factors such as age, infertility type, body mass index, anti-Müllerian hormone, basal follicle stimulating hormone, basal estrogen, antral follicle number, previous times of POR, history of ovarian surgery, ovulation stimulation protocol, average amount of gonadotropin.
Trial: 35498888
Drug: Corticosteroids combined
RxNorm normalized name: combinations of corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids combined with renin‐angiotensin system blockers (RASBs)
Trial: 33590955
Drug: 2400 mg
RxNorm normalized name: pancreatin 2400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg Aged Garlic Extract (AGE) daily for 1 year
Trial: 34990291
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of concurrent 100 mg/m2 DDP
Trial: 34990291
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of concurrent DDP
Trial: 33797427
Drug: Depo‐Medrol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo‐Medrol (40 mg/1 cc)
Trial: 33797427
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline 1 cc)
Trial: 32571395
Drug: Miao crossbow
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miao crossbow needle therapy (CN)
Trial: 34365776
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or sulfonylurea/metformin combination (Group 1)
Trial: 34365776
Drug: Thiazolidinedione combination
RxNorm normalized name: 2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazolidinedione combination (Group 2)
Trial: 34365776
Drug: Dipeptidyl peptidase‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl peptidase‐4 inhibitor (gemigliptin) combination (Group 3)
Trial: 34365776
Drug: Sodium‐glucose cotransporter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium‐glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4)
Trial: 36152018
Drug: Oral function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral function intervention (one-on-one lesson on oral exercise and preventive oral care)
Trial: 33025730
Drug: Pomalidomide 2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 2.6 mg/m2 (MTD) given orally once daily for 21 consecutive days of a 28-day cycle
Trial: 33025730
Drug: Pomalidomide 3.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 3.4 mg/m2 (dose level 3)
Trial: 32693653
Drug: Topical anaesthetic
RxNorm normalized name: Topical anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic cream (5% lidocaine‐prilocaine cream)
Trial: 32009473
Drug: Cryo-immuno-therapy (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryo-immuno-therapy (combination of cryotherapy with intralesional Candida antigen)
Trial: 32009473
Drug: Intralesional Candida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Candida antigen monotherapy
Trial: 33177808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dezocine and sufentanil (1:3, 1:1, 3:1)
Trial: 35294135
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicines
Trial: 35125219
Drug: MAS-1 adjuvanted
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS-1 adjuvanted IIV (1, 3, 5, or 9 µg per HA)
Trial: 35125219
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose IIV (Fluzone SD, 15 µg per HA)
Trial: 33762179
Drug: Comprehensive lifestyle-medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive lifestyle-medical treatment to targets and PET guided interventions
Trial: 32241789
Drug: True acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Trial: 32241789
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Trial: 34825770
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid with QR678 Neo®
Trial: 34825770
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid alone
Trial: 35940251
Drug: 5-hydroxytryptophan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (100 mg oral, twice daily for 8 weeks)
Trial: 32701419
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU, n=47)
Trial: 34153143
Drug: Clazakizumab (anti-IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (anti-IL-6 antibody)
Trial: 35195306
Drug: Oral 50
RxNorm normalized name: fat supplement, oral 50% oral emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 50 mg Zoledronic acid (ZA) once-a-week for 6 weeks
Trial: 34420816
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg a day
Trial: 36287389
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg 1% lidocaine (0.15 ml/kg)
Trial: 36287389
Drug: 0.15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 ml/kg 0.9% NaCl (placebo)
Trial: 35596730
Drug: LA-cookie (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-cookie (10 g grapeseed oil per day)
Trial: 35596730
Drug: OA-cookie (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OA-cookie (10 g high oleate safflower oil per day)
Trial: 34310352
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (swabs and BS)
Trial: 32719258
Drug: Sequential boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential boost (SEQB)
Trial: 33212063
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg by intravenous infusion every 3 weeks
Trial: 33065589
Drug: Delayed-Release Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed-Release Linaclotide 30 μg
Trial: 33065589
Drug: Delayed-Release Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed-Release Linaclotide 100 μg
Trial: 33065589
Drug: Delayed-Release Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Delayed-Release Linaclotide 300 μg
Trial: 33065589
Drug: MD-7246 (formerly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 (formerly DR2) 30 μg
Trial: 33065589
Drug: MD-7246 (formerly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 (formerly DR2) 100 μg
Trial: 33065589
Drug: MD-7246 (formerly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 (formerly DR2) 300 μg
Trial: 33065589
Drug: Immediate-Release Linaclotide
RxNorm normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate-Release Linaclotide 290 μg
Trial: 35160076
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of 20% albumin administered after induction of anesthesia
Trial: 32429851
Drug: Galcanezumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab (both doses combined)
Trial: 35122766
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) maintenance therapy
Trial: 32338316
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron (granisetron patch replaced every 7 days)
Trial: 32338316
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (8 mg thrice daily for 72 hours after chemotherapy)
Trial: 32338316
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron
Trial: 32338316
Drug: Transdermal granisetron
RxNorm normalized name: granisetron Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal granisetron and Oral ondansetron
Trial: 34280468
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin plus GLP-1RA
Trial: 34280468
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin plus daily gliflozin pill
Trial: 33687988
Drug: Flexible subcutaneous
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible subcutaneous catheter
Trial: 33314016
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality therapy (VRT) Armeo Spring® upper limb exoskeleton (Armeo), 45 minutes daily for 3 weeks
Trial: 33314016
Drug: Conventional physiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy, 45 minutes daily for 3 weeks
Trial: 35197360
Drug: Aducanumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (30 mg/kg single dose)
Trial: 35197360
Drug: Aducanumab (3-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aducanumab (3-10 mg/kg)
Trial: 36112019
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate injected at the implant-abutment interface
Trial: 36398746
Drug: Conventional Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Physical Therapy (CPT), n=5
Trial: 34605959
Drug: Yohimbine (alpha2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha2-receptor blocker)
Trial: 35806857
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g sodium butyrate daily for 12 weeks
Trial: 34051877
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg twice per day for 3 days, then once per day for 27 days)
Trial: 33331570
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) treatment during surgery
Trial: 33331570
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (Dex) treatment
Trial: 34890047
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) 100 mg/day
Trial: 34890047
Drug: Letrozole (L)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (L) 5 mg/day
Trial: 34890047
Drug: Letrozole (L)
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole (L) 2.5 mg/day + Clomiphene Citrate (CC) 50 mg/day
Trial: 35274407
Drug: Euthymic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthymic therapy (active control)
Trial: 34354699
Drug: Multidrug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidrug therapy (MDT) comprising rifampicin, dapsone, and clofazimine, 12 doses
Trial: 32151918
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise program combining weekly group sessions and home-based exercises (2/week) focusing on motor learning, flexibility, strengthening, and balance.
Trial: 35525784
Drug: Social-physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social-physical activity program (2 weekly sessions of 1 hour of physical exercise for 4 months; monthly sessions on healthy habits; 3 days of social activities)
Trial: 35435875
Drug: Benson relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson relaxation technique combined with music therapy
Trial: 32630191
Drug: Lixisenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (10 mcg)
Trial: 35263280
Drug: Intratracheal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratracheal oxygen administration
Trial: 35263280
Drug: Intranasal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxygen administration
Trial: 34119270
Drug: Combined cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined cilostazol and aspirin therapy
Trial: 33452064
Drug: Early model
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early model variables (HIE severity, epinephrine administration, respiratory support, fraction of inspired oxygen of 0.21 at admission)
Trial: 33452064
Drug: Cumulative model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative model variables (Severity of EEG findings, HIE severity, use of steroids for blood pressure management, significant brain injury on MRI)
Trial: 34215800
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin applied to the left upper back
Trial: 34215800
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical cream applied to the left upper back
Trial: 33168545
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg weekly subcutaneous for 169 days
Trial: 32014238
Drug: Participant-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant-controlled intravenous rehydration with 4% dextrose in 0.18% sodium chloride, bolus volumes of 50 ml (low volume) or 200 ml (high volume), triggered by thirst.
Trial: 36228777
Drug: Medications-first arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medications-first arm
Trial: 39215872
Drug: Carnosine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine (2 g/day)
Trial: 34986012
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT), 1500 mJ/cm2, three sessions/week for 4 weeks
Trial: 34986012
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ESWT), 0.05 mJ/mm2, one session/week for 4 weeks
Trial: 35485674
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omega 3 (flaxseed oil) 1gm three times daily for 3 months
Trial: 35485674
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose capsule) for 3 months
Trial: 32513111
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine plus 0.25 mg/kg ketamine (Group K0.25)
Trial: 32513111
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine plus 0.5 mg/kg ketamine (Group K0.5)
Trial: 32513111
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine plus 0.75 mg/kg ketamine (Group K0.75)
Trial: 32513111
Drug: Caudal ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ropivacaine plus 1.0 mg/kg ketamine (Group K1.0)
Trial: 616388369
Drug: Routine nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine nursing treatment
Trial: 33122168
Drug: Aprepitant (15-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (15-40 kg: 80 mg on days 1-3; >40 kg: 125 mg on day 1, 80 mg on days 2-3)
Trial: 33122168
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg every 8 hours for 8 days)
Trial: 33612484
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion (0.05 Unit/kg/hour)
Trial: 33612484
Drug: Standard-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose insulin infusion (0.1 Unit/kg/hour)
Trial: 33597521
Drug: TV003 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV003 vaccine
Trial: 34118470
Drug: CAD/CAM device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAD/CAM device (Narval CC™)
Trial: 35273351
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID‐19 vaccine
Trial: 33550995
Drug: Transdiagnostic psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic psychological therapy (n = 527)
Trial: 33550995
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) (n = 534)
Trial: 35984511
Drug: Heated humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated humidified high-flow nasal cannula (HFNC) oxygen therapy
Trial: 35984511
Drug: Traditional nasal
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional nasal catheter oxygen therapy
Trial: 34217960
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of echinacea angustifolia, twice daily
Trial: 34217960
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of echinacea angustifolia, twice daily
Trial: 33168881
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (CTL)
Trial: 32401086
Drug: IANB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IANB with additional buccal infiltration
Trial: 32401086
Drug: Buccal and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal and lingual anaesthetic infiltration (INF)